Background: The used first generation protease inhibitors may be hampered by virological failure in partially interferon-sensitive patients. Aim: To investigate early hepatitis C virus (HCV)-RNA decay and quasispecies modifications, and disclose viral dynamics underlying failure. Methods: Viraemia decay at early time-points during telaprevir treatment was modelled according to Neumann et al. (1998). NS3-sequences were obtained by population-sequencing and ultradeep-454-pyrosequencing. Results: 13 treatment-experienced (8 non-responders, 5 relapsers), and two cirrhotic naïve patients, received telaprevir. +. pegylated-interferon-α. +. ribavirin.Viraemia decay was biphasic. In all patients, first-phase was rapid and consistent, with a median [interquartile-range] viraemia decay of 2.8 [2.6-3.2]. log. IU/ml within 48. h. Second-phase decay was slower, especially in failing patients: 3/3 showed <1. log. IU/ml decay between 48. h and 2 weeks, and HCV-RNA >100. IU/ml at week 2. Only one patient experiencing sustained viral response showed similar kinetics.By pyrosequencing, mutational freeze was observed in all 15 patients within the first 24. h, but only in patients with sustained response afterwards. Indeed, 2/2 failing patients showed early resistance, as minor (V36A-T54A: prevalence <26% at 48. h) or major (V36M/A-R155K: prevalence, 99.8% at week 2) variants. Conclusions: Following telaprevir administration, first-phase HCV-RNA decay is consistent with mutational freeze and limited/no viral replication, while second-phase is significantly slower in failing patients (with appearance of resistance), suggesting the usefulness of early HCV-RNA monitoring.

Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice / Cento, Valeria; Tontodonati, Monica; Di Maio, Velia Chiara; Bellocchi, Maria Concetta; Valenti, Fabrizio; Manunta, Alessandra; Fortuna, Serena; Armenia, Daniele; Carioti, Luca; Antonucci, Francesco Paolo; Bertoli, Ada; Trave, Francesca; Cacciatore, Pierluigi; Angelico, Mario; Navarra, Pierluigi; Neumann, Avidan U.; Vecchiet, Jacopo; Parruti, Giustino; Babudieri, Sergio; Perno, Carlo Federico; Ceccherini-Silberstein, Francesca. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 47:3(2015), pp. 233-241. [10.1016/j.dld.2014.12.004]

Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice

MANUNTA, Alessandra;Babudieri, Sergio;
2015

Abstract

Background: The used first generation protease inhibitors may be hampered by virological failure in partially interferon-sensitive patients. Aim: To investigate early hepatitis C virus (HCV)-RNA decay and quasispecies modifications, and disclose viral dynamics underlying failure. Methods: Viraemia decay at early time-points during telaprevir treatment was modelled according to Neumann et al. (1998). NS3-sequences were obtained by population-sequencing and ultradeep-454-pyrosequencing. Results: 13 treatment-experienced (8 non-responders, 5 relapsers), and two cirrhotic naïve patients, received telaprevir. +. pegylated-interferon-α. +. ribavirin.Viraemia decay was biphasic. In all patients, first-phase was rapid and consistent, with a median [interquartile-range] viraemia decay of 2.8 [2.6-3.2]. log. IU/ml within 48. h. Second-phase decay was slower, especially in failing patients: 3/3 showed <1. log. IU/ml decay between 48. h and 2 weeks, and HCV-RNA >100. IU/ml at week 2. Only one patient experiencing sustained viral response showed similar kinetics.By pyrosequencing, mutational freeze was observed in all 15 patients within the first 24. h, but only in patients with sustained response afterwards. Indeed, 2/2 failing patients showed early resistance, as minor (V36A-T54A: prevalence <26% at 48. h) or major (V36M/A-R155K: prevalence, 99.8% at week 2) variants. Conclusions: Following telaprevir administration, first-phase HCV-RNA decay is consistent with mutational freeze and limited/no viral replication, while second-phase is significantly slower in failing patients (with appearance of resistance), suggesting the usefulness of early HCV-RNA monitoring.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11388/211900
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact